Profile data is unavailable for this security.
About the company
Aarti Drugs Limited is an India-based company, which is engaged in manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include iprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole, ofloxacin, and others. Its specialty chemicals includes benzene sulphonyl chloride, methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include alpha lipoic acid, itraconazole, ticagrelor, and sitagliptin. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited, and Pinnacle Chile SPA.
- Revenue in INR (TTM)23.80bn
- Net income in INR1.52bn
- Incorporated1984
- Employees1.06k
- LocationAarti Drugs LtdMahendra Industrial Estate,Ground Floor, Road No 29, Plot No 109-D,MUMBAI 400022IndiaIND
- Phone+91 2 224019025
- Fax+91 2 224073462
- Websitehttps://www.aartidrugs.co.in/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Themis Medicare Ltd | 4.20bn | 529.90m | 25.43bn | 1.54k | 48.04 | 6.17 | 39.74 | 6.05 | 5.75 | 5.75 | 45.63 | 44.76 | 0.7306 | 2.39 | 2.22 | 2,727,670.00 | 9.21 | 11.12 | 12.57 | 16.46 | 64.64 | 60.32 | 12.61 | 14.96 | 1.56 | -- | 0.1651 | 7.59 | 7.74 | 15.75 | -23.51 | -- | 26.73 | -- |
| Indoco Remedies Ltd | 17.73bn | 320.40m | 28.31bn | 5.93k | 92.09 | 2.60 | 20.77 | 1.60 | 3.34 | 3.34 | 175.26 | 118.23 | 0.8194 | 1.52 | 4.51 | 2,989,727.00 | 1.36 | 6.88 | 1.99 | 9.85 | 68.34 | 65.59 | 1.66 | 6.93 | 0.8142 | 1.71 | 0.4339 | 14.02 | 8.91 | 13.41 | -30.78 | -- | 34.54 | 37.97 |
| Dishman Carbogen Amcis Ltd | 24.16bn | -2.48bn | 29.89bn | 1.13k | -- | -- | 173.08 | 1.24 | -15.81 | -15.81 | 154.06 | -- | -- | -- | -- | 21,344,260.00 | -- | -0.3986 | -- | -0.4888 | 79.30 | 73.83 | -10.27 | -1.54 | -- | -0.7216 | -- | -- | 8.41 | 4.91 | -414.93 | -- | -0.3175 | -- |
| RPG Life Sciences Limited | 6.18bn | 706.60m | 37.32bn | 1.27k | 52.82 | 9.84 | 41.52 | 6.04 | 42.72 | 42.72 | 373.86 | 229.38 | 1.22 | 1.99 | 8.44 | 4,868,662.00 | 13.92 | 16.07 | 19.35 | 21.77 | 67.85 | 62.99 | 11.43 | 11.99 | 1.45 | 207.32 | 0.00 | 29.27 | 13.50 | 12.01 | 29.60 | 51.98 | 28.60 | 46.14 |
| Solara Active Pharma Sciences Ltd | 12.22bn | -5.36bn | 42.36bn | 2.16k | -- | 2.52 | -- | 3.47 | -137.13 | -137.13 | 320.29 | 301.63 | 0.4731 | 1.77 | 2.69 | 5,667,023.00 | -20.76 | -2.44 | -36.40 | -3.84 | 38.70 | 41.16 | -43.89 | -4.49 | 0.448 | -1.30 | 0.4355 | -- | -10.73 | -1.45 | -2,458.12 | -- | -4.81 | -- |
| Aarti Drugs Ltd | 23.80bn | 1.52bn | 43.45bn | 1.06k | 28.64 | 3.40 | 21.13 | 1.83 | 16.62 | 16.62 | 259.74 | 139.96 | 0.9954 | 3.16 | 3.43 | 22,364,630.00 | 6.37 | 9.73 | 9.62 | 15.78 | 34.60 | 22.23 | 6.40 | 8.25 | 1.01 | 6.83 | 0.3159 | -- | -6.90 | 10.13 | 3.07 | 13.82 | 24.96 | -- |
| Morepen Laboratories Ltd | 17.45bn | 1.18bn | 43.73bn | 1.62k | 34.54 | -- | 29.23 | 2.51 | 2.31 | 2.31 | 34.26 | -- | -- | -- | -- | 10,749,300.00 | -- | 7.90 | -- | 13.34 | 37.86 | 33.34 | 6.77 | 5.49 | -- | 33.34 | -- | 0.00 | 19.25 | 17.08 | 148.63 | 27.22 | 47.03 | -- |
| Jeena Sikho Lifecare Ltd | -100.00bn | -100.00bn | 44.58bn | 1.23k | -- | 141.00 | -- | -- | -- | -- | -- | 12.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.8228 | -- | 0.2681 | -- | 43.84 | -- | 77.37 | -- | -- | -- |
| Gufic BioSciences Ltd | 8.14bn | 863.69m | 45.25bn | 1.45k | 51.88 | -- | 43.74 | 5.56 | 8.70 | 8.70 | 81.95 | -- | -- | -- | -- | 5,624,707.00 | -- | 11.46 | -- | 19.21 | 52.39 | 45.79 | 10.60 | 10.46 | -- | 8.09 | -- | 1.31 | 16.80 | 18.12 | 8.07 | 31.46 | 53.83 | 14.87 |
| Hikal Ltd | 18.03bn | 677.82m | 47.43bn | 2.06k | 70.01 | -- | 25.03 | 2.63 | 5.49 | 5.49 | 145.97 | -- | -- | -- | -- | 8,749,879.00 | -- | 5.07 | -- | 7.51 | 53.06 | 46.78 | 3.76 | 5.86 | -- | 2.45 | -- | 12.19 | -11.79 | 2.34 | -11.20 | -7.55 | 9.72 | 0.00 |
| Supriya Lifescience Ltd | 6.25bn | 1.58bn | 51.34bn | 448.00 | 32.64 | 5.67 | 29.37 | 8.21 | 19.54 | 19.54 | 77.55 | 112.56 | 0.6737 | 2.01 | 6.56 | 13,950,510.00 | 16.98 | 19.08 | 18.38 | 24.04 | 66.81 | 57.12 | 25.20 | 24.71 | 4.05 | 111.46 | 0.006 | 2.88 | 23.74 | 15.47 | 32.56 | 24.75 | 83.79 | -- |
| SeQuent Scientific Ltd | 14.27bn | 54.87m | 51.43bn | 1.20k | 965.27 | -- | 66.20 | 3.60 | 0.2137 | 0.2137 | 57.18 | -- | -- | -- | -- | 11,939,190.00 | -- | 1.09 | -- | 1.76 | 45.38 | 41.97 | 0.9902 | 1.18 | -- | 0.9009 | -- | 35.06 | -3.60 | 5.68 | 70.40 | -- | 6.96 | -- |
| Innova Captab Ltd | 11.78bn | 1.18bn | 54.60bn | -- | 38.10 | 6.10 | 39.99 | 4.64 | 25.04 | 25.04 | 232.86 | 156.45 | 0.903 | 4.83 | 3.74 | -- | 9.07 | 10.82 | 12.50 | 18.38 | 34.06 | 25.18 | 10.05 | 8.04 | 1.32 | 19.79 | 0.2259 | -- | 16.72 | 24.90 | 38.84 | 36.55 | 104.14 | -- |
| Aarti Pharmalabs Ltd | 19.68bn | 2.28bn | 59.33bn | 1.63k | 26.02 | 3.20 | 19.32 | 3.01 | 25.16 | 25.16 | 217.12 | 204.88 | 0.7733 | 1.62 | 4.59 | 12,095,750.00 | 8.96 | -- | 11.86 | -- | 45.56 | -- | 11.59 | -- | 0.9611 | 17.12 | 0.1723 | -- | -4.76 | -- | 12.10 | -- | -- | -- |
Data as of Nov 13 2024. Currency figures normalised to Aarti Drugs Ltd's reporting currency: Indian Rupee INR
8.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| DSP Asset Managers Pvt. Ltd.as of 30 Sep 2024 | 5.41m | 5.88% |
| ICICI Prudential Asset Management Co. Ltd.as of 31 Oct 2024 | 860.03k | 0.94% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 627.94k | 0.68% |
| Mellon Investments Corp.as of 03 Oct 2024 | 265.28k | 0.29% |
| BlackRock Advisors (UK) Ltd.as of 03 Oct 2024 | 114.69k | 0.13% |
| BlackRock Fund Advisorsas of 03 Oct 2024 | 104.10k | 0.11% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Oct 2024 | 79.70k | 0.09% |
| SSgA Funds Management, Inc.as of 03 Oct 2024 | 52.78k | 0.06% |
| TIAA-CREF Investment Management LLCas of 31 Aug 2024 | 33.65k | 0.04% |
| State Street Global Advisors Ltd.as of 02 Oct 2024 | 32.43k | 0.04% |
More ▼
Data from 30 Jun 2024 - 07 Nov 2024Source: FactSet Research Systems Inc.
